| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 817 | 2021 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 148 | 2022 |
| ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma CO Demirtas, A D’Alessio, L Rimassa, R Sharma, DJ Pinato JHEP Reports 3 (5), 100347, 2021 | 106 | 2021 |
| T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma M Barsch, H Salié, AE Schlaak, Z Zhang, M Hess, LS Mayer, C Tauber, ... Journal of Hepatology 77 (2), 397-409, 2022 | 79 | 2022 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 71 | 2022 |
| Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 55 | 2022 |
| Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 53 | 2021 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 51 | 2021 |
| Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score … B Marinelli, E Kim, A D'Alessio, M Cedillo, I Sinha, N Debnath, M Kudo, ... Journal for immunotherapy of cancer 10 (6), 2022 | 42 | 2022 |
| Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials CAM Fulgenzi, A D'Alessio, C Airoldi, L Scotti, CO Demirtas, A Gennari, ... European Journal of Cancer 174, 57-67, 2022 | 31 | 2022 |
| Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab YL Wu, CAM Fulgenzi, A D’Alessio, J Cheon, N Nishida, A Saeed, ... Cancers 14 (23), 5834, 2022 | 30 | 2022 |
| Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma A Muhammed, A D’Alessio, A Enica, T Talbot, CAM Fulgenzi, ... Expert Review of Molecular Diagnostics 22 (3), 253-264, 2022 | 27 | 2022 |
| Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials CAM Fulgenzi, B Scheiner, J Korolewicz, CV Stikas, A Gennari, ... JHEP Reports 5 (5), 100702, 2023 | 26 | 2023 |
| Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase … A Cortellini, B Ricciuti, H Borghaei, AR Naqash, A D'Alessio, ... Cancer 128 (16), 3067-3079, 2022 | 22 | 2022 |
| Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma B Scheiner, D Roessler, S Phen, M Lim, K Pomej, T Pressiani, ... JHEP reports 5 (1), 100620, 2023 | 21 | 2023 |
| Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study Q Zeng, C Klein, S Caruso, P Maille, DS Allende, B Mínguez, M Iavarone, ... The Lancet Oncology 24 (12), 1411-1422, 2023 | 20 | 2023 |
| PD-1 blockade for hepatocellular carcinoma: current research and future prospects A D’Alessio, L Rimassa, A Cortellini, DJ Pinato Journal of Hepatocellular Carcinoma, 887-897, 2021 | 20 | 2021 |
| Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study T Talbot, A D'Alessio, M Pinter, L Balcar, B Scheiner, TU Marron, T Jun, ... Liver International 43 (3), 695-707, 2023 | 19* | 2023 |
| Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations A Cortellini, B Ricciuti, VR Vaz, D Soldato, JV Alessi, FG Dall’Olio, ... Journal for immunotherapy of cancer 10 (2), 2022 | 19 | 2022 |
| The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together A D’Alessio, A Cammarota, MG Prete, T Pressiani, L Rimassa Current Opinion in Oncology 33 (4), 386-394, 2021 | 19 | 2021 |
Claudia Angela Maria FulgenziImperial College London在 imperial.ac.uk 的电子邮件经过验证
Claudia Angela Maria FulgenziImperial College London在 imperial.ac.uk 的电子邮件经过验证